home All News open_in_new Full Article

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions  GlobeNewswire


today 3 w. ago attach_file Science

attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Science
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events


ID: 120217721
Add Watch Country

arrow_drop_down